# Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

> **NCT03626714** · EARLY_PHASE1 · COMPLETED · sponsor: **Auritec Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Organ Transplant Rejection
- Psoriasis

## Interventions

- **DRUG:** Sustained Release Injectable Tacrolimus

## Key facts

- **NCT ID:** NCT03626714
- **Lead sponsor:** Auritec Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-16
- **Primary completion:** 2019-01-05
- **Final completion:** 2019-01-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03626714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03626714, "Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03626714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*